IDYA Ideaya Biosciences announces ide892, a potential best-in-class mta-cooperative prmt5 inhibitor, initiates part 2 monotherapy expansion
IDYA Ideaya Biosciences announces ide892, a potential best-in-class mta-cooperative prmt5 inhibitor, initiates part 2 monotherapy expansion in the phase 1/2 study in mtap-deleted pancreatic and lung cancers